human proximal renal tubular epithelial cell line (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
human proximal renal tubular epithelial cell line
Human Proximal Renal Tubular Epithelial Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 4550 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+renal+proximal+tubular+epithelial+cell+lines+hk+2/HK-2/pm42262012-93-0-11
Average 99 stars, based on 4550 article reviews
Human Proximal Renal Tubular Epithelial Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 4550 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+renal+proximal+tubular+epithelial+cell+lines+hk+2/HK-2/pm42262012-93-0-11
Average 99 stars, based on 4550 article reviews
human proximal renal tubular epithelial cell line - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
other:Article Title: Identification of selective homeodomain interacting protein kinase 2 inhibitors, a potential treatment for renal fibrosis. Article Snippet: Homeodomain interacting protein kinase 2 (HIPK2) has emerged as a promising target for the discovery of antirenal fibrosis drugs.. Herein, to develop specific pharmacologic inhibitors of HIPK2, we designed and synthesized a series of compounds containing benzimidazole and pyrimidine scaffolds via fragment-based drug design strategy.. Kinase assay was applied to evaluate the inhibitory activity of target compounds against HIPKs enzyme. Article Title: Design, synthesis, and in vitro anti-renal fibrotic effects of imidazopyridazine-based homeodomain-interacting protein kinase 2 inhibitors. Article Snippet: Renal fibrosis, a progressive pathology in chronic kidney disease (CKD), is primarily driven by HIPK2 (homeodomain-interacting protein kinase 2)-mediated activation of the TGF-β/Smad3 and NF-κB signaling pathways, leading to excessive extracellular matrix deposition and inflammation.. Current therapeutic strategies targeting HIPK2 show limited efficacy, highlighting the need for more effective inhibitors.. We developed compound c4 through rational optimization of the lead compound CHR-6494. |